Ledipasvir-sofosbuvir for treating Japanese patients with chronic hepatitis C virus genotype 2 infection.
Yasuhiro AsahinaYoshito ItohYoshiyuki UenoYasushi MatsuzakiYasuhiro TakikawaHiroshi YatsuhashiTakuya GendaFusao IkedaTakuma MatsudaHadas Dvory-SobolDeyuan JiangBenedetta MassettoAnu O OsinusiDiana M BrainardJohn G McHutchisonNorifumi KawadaNobuyuki EnomotoPublished in: Liver international : official journal of the International Association for the Study of the Liver (2018)
Among Japanese patients with HCV genotype 2, 12 weeks of treatment with ledipasvir-sofosbuvir resulted in high rates of SVR12 that were non-inferior to sofosbuvir + ribavirin.